全文获取类型
收费全文 | 3203篇 |
免费 | 121篇 |
国内免费 | 34篇 |
专业分类
耳鼻咽喉 | 46篇 |
儿科学 | 70篇 |
妇产科学 | 94篇 |
基础医学 | 531篇 |
口腔科学 | 93篇 |
临床医学 | 239篇 |
内科学 | 701篇 |
皮肤病学 | 45篇 |
神经病学 | 262篇 |
特种医学 | 132篇 |
外科学 | 495篇 |
综合类 | 10篇 |
预防医学 | 135篇 |
眼科学 | 85篇 |
药学 | 288篇 |
中国医学 | 9篇 |
肿瘤学 | 123篇 |
出版年
2022年 | 24篇 |
2021年 | 26篇 |
2020年 | 22篇 |
2019年 | 24篇 |
2018年 | 31篇 |
2017年 | 29篇 |
2016年 | 35篇 |
2015年 | 54篇 |
2014年 | 73篇 |
2013年 | 89篇 |
2012年 | 125篇 |
2011年 | 141篇 |
2010年 | 99篇 |
2009年 | 106篇 |
2008年 | 184篇 |
2007年 | 204篇 |
2006年 | 187篇 |
2005年 | 214篇 |
2004年 | 238篇 |
2003年 | 225篇 |
2002年 | 201篇 |
2001年 | 44篇 |
2000年 | 50篇 |
1999年 | 50篇 |
1998年 | 53篇 |
1997年 | 31篇 |
1996年 | 34篇 |
1995年 | 37篇 |
1994年 | 40篇 |
1993年 | 43篇 |
1992年 | 26篇 |
1991年 | 29篇 |
1990年 | 21篇 |
1989年 | 24篇 |
1988年 | 25篇 |
1987年 | 26篇 |
1986年 | 15篇 |
1985年 | 14篇 |
1984年 | 21篇 |
1983年 | 23篇 |
1982年 | 24篇 |
1981年 | 26篇 |
1980年 | 30篇 |
1979年 | 12篇 |
1978年 | 17篇 |
1977年 | 19篇 |
1976年 | 12篇 |
1975年 | 25篇 |
1961年 | 17篇 |
1954年 | 12篇 |
排序方式: 共有3358条查询结果,搜索用时 15 毫秒
91.
Initial experience with paclitaxel-coated stents 总被引:5,自引:0,他引:5
Local delivery of immunosuppressive or antiproliferative agents using a drug-eluting stent is a new technology that is supposed to inhibit in-stent restenosis, thus providing a biological and mechanical solution. This technique is a very promising. To date, several agents have been used, including paclitaxel, QP-2, rapamycin, actinomycin D, dexamethason, tacrolimus, and everolimus. Several studies, published recently or still ongoing, have evaluated these drugs as to their release kinetics, effective dosage, safety in clinical practice, and benefit. These studies include: SCORE (paclitaxel derivative), TAXUS I-VI, ELUTES, ASPECT, DELIVER (paclitaxel), RAVEL, SIRIUS (sirolimus), ACTION (actinomycin), EVIDENT, PRESENT (tacrolimus), EMPEROR (dexamethason), and FUTURE (everolimus). Paclitaxel was one of the first stent-based antiproliferative agents under clinical investigation that provided profound inhibition of neointimal thickening depending on delivery duration and drug dosage. The randomized, multicenter SCORE trail (Quanam stent, paclitaxel-coated) enrolled 266 patients at 17 sites. At 6-month's follow-up, a drop of 83% in stent restenosis using the drug-eluting stent could be achieved (6.4% drug-eluting stent vs 36.9% control group), which was attributable to a remarkable decrease in intimal proliferation. Unfortunately, due to frequent stent thrombosis and side-branch occlusions, the reported 30-day MACE rate was 10.2%. The randomized TAXUS-I safety trial (BSC, NIRx, paclitaxel-coated) also demonstrated beneficial reduction of restenotic lesions at 6-month's follow-up (0% vs 10%) but was associated with the absence of thrombotic events presumably due to less drug dosage. The ongoing TAXUS II-VI trials are addressing additional insight regarding the efficacy of the TAXUS paclitaxel-eluting stent. ASPECT and ELUTES evaluated paclitaxel-coated stents (i.e., Cook and Supra G), including subgroups with different drug dosages. With respect to stent restenosis and neointimal proliferation, both studies demonstrated a clear dose response. The RAVEL and the SIRIUS trials evaluated sirolimus-coated stents (i.e., Cordis, Johnson & Johnson, and Bx VELOCITY stents). Results confirmed the beneficial findings regarding reduction of renarrowing using a drug-eluting stent without any major adverse effects. Although parameters such as drug toxicity, optimal drug dosage, or delayed endothelial healing still need to be evaluated, today's clinical experience indicates that drug-coated stents are extremely beneficial in the interventional treatment of coronary lesions. 相似文献
92.
93.
Fickelscher I Starke H Schulze E Ernst G Kosyakova N Mkrtchyan H MacDermont K Sebire N Liehr T 《Prenatal diagnosis》2007,27(8):783-785
A prenatally ascertained case with a de novo small supernumerary marker chromosome (sSMC) derived from chromosome 1 is reported. Due to a fetal heart defect the parents decided in favour of an induced abortion. Postmortem, a molecular cytogenetic study on eleven formalin fixed, paraffin-embedded tissues of the fetus was performed, to further characterize the levels of mosaicism of the sSMC(1). sSMC presence varied between 13 and 62% within different tissues of sSMC carriers. This finding is something common in sSMC carriers and could explain why up to the present no clinical correlations for sSMC mosaicism and clinical outcome in the corresponding carriers could be established. 相似文献
94.
95.
Johannes Frank Camilla M. A. Carroll Karen Aaranson Lazarre Ogden Michael Kim Gary L. Anderson Laura Swietzer Sheldon J. Bond Eberhard Uhl John H. Barker 《Microsurgery》1996,17(8):452-456
The aim of this study was to investigate the angiogenic response to exogenously administered basic fibroblast growth factor (FGF-2) in normal and ischemic skin, using the hairless mouse ear microcirculatory model. The hairless mouse ear is a well-established model for in vivo studies of skin microcirculation. Using this model, angiogenesis- and angiogenesis-associated changes in the microcirculation can be directly and continuously viewed and quantified in a variety of different experimental settings. To create ischemia in the mouse ear, all but one of the three to four feeding vessels nourishing the ear were ligated 3 days prior to a local subdermal injection of FGF-2 (9.3 + 1–0.5 mm/mm2) or saline into the dorsum of the ears. Angiogenesis was quantified by direct observation, at high magnification, of the injection site where increases in total vessel length (TVL) were measured repeatedly over 18 days following injection. We found a significant (P < 0.01) increase in TVL in normal and ischemic ears injected with FGF-2. Saline injection also induced a significant increase in TVL in ischemic ears. However, the angiogenic response to FGF-2 in ischemic ears was significantly stronger than saline alone in ischemic ears or saline or FGF-2 in normal ears. This response could be used clinically to accelerate angiogenesis and thus increase perfusion in ischemic tissue. © 1997 Wiley-Liss, Inc. MICROSURGERY 17:452–456 1996 相似文献
96.
Raimund W. Kinne Carsten B. Schmidt-Weber Ralph Hoppe Eberhard Buchner Ernesta Palombo-Kinne Eberhard Nürnberg Frank Emmrich 《Arthritis \u0026amp; Rheumatology》1995,38(12):1777-1790
Objective. To determine whether systemic elimination of macrophages by means of clodronate-containing liposomes counteracts inflammation and joint destruction in rats with established adjuvant arthritis (AA). Methods. Rats with AA received a total of 2.7 mg of clodronate encapsulated in liposomes in 3 intravenous doses on days 10, 11, and 12 of arthritis. Phosphate buffered saline (PBS), PBS-laden liposomes, or free clodronate were used as negative controls. Clinical, hematologic, and histopathologic signs of AA were monitored, and depletion of macrophages by clodronate-liposomes was evaluated both in the synovial membrane (SM) and in organs of the mononuclear phagocyte system (MPS). Results. Clodronate-laden liposomes led to significant, long-term amelioration of the clinical signs of AA, a reduction in the erythrocyte sedimentation rate (ESR), and counteraction of joint destruction, not only immediately after treatment, but also for 2 weeks thereafter. Free clodronate induced moderate clinical improvement and a significant decrease in the ESR, but only during the late phase of AA. Drug-free vesicles even aggravated the joint destruction. Clodronate-laden liposomes did not induce significant depletion of resident macrophages in the SM, but rather, in the paracortical region of popliteal lymph nodes, in the liver, and in the marginal zone and periarteriolar lymphatic sheaths of the spleen. Conclusion. Clodronate-laden liposomes induce long-term amelioration of AA, even if administered for a brief period during the florid phase of the disease. The amelioration is paralleled by the elimination of macrophages in immunocompetent areas of the spleen and draining lymph nodes, but not locally in the SM. This suggests an influence of the treatment on the immunoregulatory rather than effector, functions of macrophages. 相似文献
97.
Windler Eberhard Baum Erika Bhling Kai J. Taute Bettina-Maria Stute Petra Ortmann Olaf 《Gyn?kologische Endokrinologie》2020,18(1):16-19
Gynäkologische Endokrinologie - Auch die neue Version der AWMF-S3-Leitlinie „Peri- und Postmenopause – Diagnostik und Interventionen“ der Deutschen Gesellschaft für... 相似文献
98.
99.
Fabian Falkenstein Marco Gessi Daniela Kandels Ho-Keung Ng René Schmidt Monika Warmuth-Metz Brigitte Bison Juergen Krauss Rolf-Dieter Kortmann Beate Timmermann Ulrich-Wilhelm Thomale Michael H. Albert Arnulf Pekrun Eberhard Maaß Astrid K. Gnekow Torsten Pietsch 《International journal of cancer. Journal international du cancer》2020,147(8):2159-2175
Reports on pediatric low-grade diffuse glioma WHO-grade II (DG2) suggest an impaired survival rate, but lack conclusive results for genetically defined DG2-entities. We analyzed the natural history, treatment and prognosis of DG2 and investigated which genetically defined sub-entities proved unfavorable for survival. Within the prospectively registered, population-based German/Swiss SIOP-LGG 2004 cohort 100 patients (age 0.8-17.8 years, 4% neurofibromatosis [NF1]) were diagnosed with a DG2. Following biopsy (41%) or variable extent of resection (59%), 65 patients received no adjuvant treatment. Radiologic progression or severe neurologic symptoms prompted chemotherapy (n = 18) or radiotherapy (n = 17). Multiple lines of salvage treatment were necessary for 19/35 patients. Five years event-free survival dropped to 0.44, while 5 years overall survival was 0.90 (median observation time 8.3 years). Extensive genetic profiling of 65/100 DG2 identified Histone3-K27M-mutation in 4, IDH1-mutation in 11, BRAF-V600-mutation in 12, KIAA1549-BRAF-fusions in 6 patients, while the remaining 32 tumor tissues did not show alterations of these genes. Progression to malignant glioma occurred in 12 cases of all genetically defined subgroups within a range of 0.5 to 10.8 years, except for tumors carrying KIAA1549-BRAF-fusions. Histone3-K27M-mutant tumors proved uniformly fatal within 0.6 to 2.4 years. The current LGG treatment strategy seems appropriate for all DG2-entities, with the exemption of Histone3-K27M-mutant tumors that require a HGG-related treatment strategy. Our data confirm the importance to genetically define pediatric low-grade diffuse gliomas for proper treatment decisions and risk assessment. 相似文献